In a patient with confirmed severe primary IGF‑1 deficiency or growth hormone insensitivity who has failed adequate GH therapy, how should recombinant human IGF‑1 (mecasermin) be initiated, dosed, and monitored?

Management of Severe Primary IGF-1 Deficiency with Mecasermin

In patients with confirmed severe primary IGF-1 deficiency or growth hormone insensitivity who have failed adequate GH therapy, initiate mecasermin at 0.04-0.08 mg/kg subcutaneously twice daily, administered shortly before or after meals to prevent hypoglycemia, with dose escalation by 0.04 mg/kg per dose weekly if tolerated, up to a maximum of 0.12 mg/kg twice daily. 1

Patient Eligibility Criteria

Before initiating mecasermin, confirm the following diagnostic criteria:

• Age ≥2 years (safety not established in younger children) 1
• Severe primary IGF-1 deficiency: IGF-1 SDS ≤-3 with normal or elevated GH levels 2, 3
• Height SDS ≤-3 with documented growth failure 2, 4
• Failed adequate GH therapy OR GH gene deletion with neutralizing antibodies to GH 1

Critical contraindications that must be ruled out include closed epiphyses, active malignancy, and known hypersensitivity to mecasermin 1.

Dosing Algorithm

Initial Dosing

Start conservatively at 0.04-0.08 mg/kg subcutaneously twice daily 1. This lower starting dose minimizes the risk of hypoglycemia, which is the most common serious adverse effect.

Dose Escalation Protocol

• Week 1: Assess tolerance at starting dose
• If well-tolerated after 1 week: Increase by 0.04 mg/kg per dose 1
• Continue weekly escalations until reaching target maintenance dose
• Maximum dose: 0.12 mg/kg twice daily 1

The FDA label is explicit about this stepwise approach—do not rush dose escalation 1.

Administration Technique

Timing is critical: Administer mecasermin shortly before or after a meal or snack because it has potent insulin-like hypoglycemic effects 1. This is non-negotiable given the risk of severe hypoglycemia and seizures.

Rotate injection sites to avoid lipohypertrophy 1. Subcutaneous administration in the abdomen, thigh, or upper arm is appropriate.

Monitoring Protocol

Initial Phase (First 6 Months)

Monitor patients closely during dose titration:

• Clinical assessment at 1-2 month intervals during titration 5
• Glucose monitoring: Educate families on hypoglycemia recognition and management 1
• Height velocity and weight at each visit
• IGF-1 levels after dose stabilization (though less critical than with GH therapy, as you're replacing IGF-1 directly)

Maintenance Phase (After Dose Stabilization)

Once maintenance dose is achieved, monitor semiannually 5:

• Height velocity and height SDS (expect greatest gains in first year, diminishing thereafter) 6, 4, 7
• Weight and BMI (both typically increase significantly) 4
• Funduscopic examination periodically to detect intracranial hypertension 1
• Tonsillar/adenoidal examination for hypertrophy 1
• Hip/knee examination to detect slipped capital femoral epiphysis 1
• Scoliosis monitoring if present 1

Annual Assessments

• Fasting glucose and lipid profile 5
• Bone age radiograph to track advancement relative to chronological age 1
• Thyroid and adrenal function if patient has hypopituitarism 8, 5

Expected Outcomes and Treatment Duration

Height velocity response: Expect mean increase of approximately 5.2 cm/year in first year, declining to 2.9 cm/year in second year and further thereafter 1. The greatest treatment effect occurs early, particularly in treatment-naïve prepubertal patients 7.

Height SDS gain: Average improvement of 0.9 SDS to near-adult height in real-world data, with treatment-naïve prepubertal patients achieving 1.4 SDS gain 7. Almost half of prepubertal patients can reach near-adult height within the normal range if started early 7.

Treatment duration: Continue until epiphyseal closure. Median treatment duration in registry data was 3.9 years, though some patients require longer therapy 7.

Critical Safety Considerations

Hypoglycemia (Most Important)

40-50% of patients experience hypoglycemia 6, 4. This is the primary safety concern:

• Always administer with food 1
• Educate families on recognition and emergency management
• Severe hypoglycemic seizures have been reported 1
• Most episodes are mild and manageable with dose adjustment 9

Malignancy Risk

Several cases of malignant neoplasia have been observed in pediatric patients treated with mecasermin 1. While causality is uncertain, discontinue immediately if malignancy develops and seek expert oncologic care 1.

Other Adverse Effects

• Tonsillar/adenoidal hypertrophy: Common, may require ENT evaluation 1
• Intracranial hypertension: Requires funduscopic monitoring 1
• Slipped capital femoral epiphysis: Evaluate any limp or hip/knee pain promptly 1
• Allergic reactions including anaphylaxis: Rare but reported; interrupt treatment if systemic reaction occurs 1

Benzyl Alcohol Preservative

Mecasermin contains benzyl alcohol, which has been associated with serious adverse reactions in neonates and infants. Use in infants is not recommended 1.

Storage and Handling

• Before opening: Refrigerate at 2-8°C (36-46°F) 1
• After opening: Stable for 30 days when refrigerated 1
• Never freeze; protect from direct light 1
• Discard unused material after 30 days 1

Special Populations

Laron syndrome patients: Despite treatment, only 10.5% reach near-adult height within normal range, reflecting the severity of their condition 7. However, meaningful height gains still occur.

Patients with GH gene deletion and neutralizing antibodies: Mecasermin is specifically indicated for this population when GH therapy has failed 1.

Common Pitfalls to Avoid

1. Administering without food: This is the most common error leading to hypoglycemia
2. Starting at maximum dose: Always start low and titrate slowly
3. Inadequate family education: Families must understand hypoglycemia risk and management
4. Delayed initiation: Earlier treatment (prepubertal, treatment-naïve) yields better outcomes 7
5. Inadequate monitoring: Missing intracranial hypertension, SCFE, or malignancy development
6. Using in infants: Not recommended due to benzyl alcohol content 1

Adjunctive Considerations

If the patient has hypopituitarism with multiple hormone deficiencies:

• Ensure adequate glucocorticoid replacement before or concurrent with mecasermin 8
• Optimize thyroid hormone replacement (may need adjustment after starting treatment) 8, 5
• Monitor for interactions between replacement hormones 8

The evidence base for mecasermin is robust from FDA approval studies and real-world registry data 1, 7, though most experience is in severely affected patients with Laron syndrome phenotype 3. The drug is effective but requires meticulous attention to hypoglycemia prevention and monitoring for serious adverse effects.